Key statistics
As of last trade Arvinas Inc (ARVN:NSQ) traded at 13.10, -30.80% below its 52-week high of 18.93, set on Mar 06, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 12.85 |
|---|---|
| High | 13.42 |
| Low | 12.89 |
| Bid | 13.05 |
| Offer | 13.15 |
| Previous close | 13.39 |
| Average volume | 988.50k |
|---|---|
| Shares outstanding | 63.96m |
| Free float | 58.91m |
| P/E (TTM) | -- |
| Market cap | 856.44m USD |
| EPS (TTM) | -1.22 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 15:25 GMT.
More ▼
- Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Arvinas to Participate in Upcoming Investor Conferences
- Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
- Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
- Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
- Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
- Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
- Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
- Arvinas to Participate in Upcoming Investor Conferences
More ▼
